Leqembi Gathers Pace with Sales Up 2.7-Fold in January-March: Eisai

The launch uptake of Alzheimer’s therapy Leqembi (lecanemab) is picking up steam, with its global revenue nearly tripling in the latest January-March quarter, according to Eisai’s preliminary report released on April 24. In January-March, Leqembi generated 2.83 billion yen on...read more